MBX Biosciences, Inc. (MBX) Stock Forecast
MBX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.73 / 5 from 11 analysts
- Price target
- $95.70 average of analyst targets
- Upside to target
- +92.9% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.80
- 52-week range
- $14.23 – $70.70
MBX analyst ratings
11 analystsNumber of analysts at each rating.
MBX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MBX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.84 | −$0.96 | −$0.74 | −$0.63 | −34.1% | 7 |
| Current fiscal year (2026) | −$3.05 | −$3.30 | −$2.91 | −$2.38 | −28.3% | 8 |
| Next fiscal year (2027) | −$3.98 | −$4.50 | −$3.64 | −$3.05 | −30.2% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MBX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 7 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 8 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 8 |
MBX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MBX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.74 | −$0.84 | −$0.84 | −$0.84 | −$0.84 | +14.4% | 0 up · 4 down |
| Current fiscal year (2026) | −$2.75 | −$3.11 | −$3.11 | −$3.05 | −$3.05 | +11.1% | 1 up · 3 down |
| Next fiscal year (2027) | −$3.93 | −$3.94 | −$3.96 | −$3.98 | −$3.98 | +1.2% | 0 up · 5 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MBX earnings surprises
Reported EPS vs the consensus estimate for the last 9 quarters; MBX beat in 6 of 9.
What analysts expect from MBX
11 analysts cover MBX Biosciences; their consensus rating is strong buy (4.73 on a 1–5 scale, where 5 is a strong buy). The average price target is $95.70, 92.9% above the latest close of $49.61. Analysts expect earnings of −$3.05 per share for 2026, −28.3% from a year earlier. For 2027 the average estimate is −$3.98 per share. MBX Biosciences beat the EPS estimate in 6 of the last 9 quarters.
Related: MBX income statement, MBX key metrics, MBX chart. See the MBX stock overview for the latest quote and news.
MBX forecast FAQ
What is MBX Biosciences's price target?
The average analyst price target for MBX Biosciences is $95.70, 92.9% above the latest close of $49.61.
Is MBX Biosciences a buy, hold or sell?
Of 11 analysts covering MBX Biosciences, 8 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is MBX Biosciences's EPS forecast?
Analysts forecast −$3.05 per share for 2026 (range −$3.30 to −$2.91); for 2027 the estimate is −$3.98.
When does MBX Biosciences report earnings?
MBX Biosciences is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.80.
Does MBX Biosciences usually beat earnings estimates?
MBX Biosciences reported EPS at or above the analyst estimate in 6 of the last 9 quarters.